Cue Biopharma, Inc. (FRA:1UC0)
Germany · Delayed Price · Currency is EUR | Market Cap | 121.05M +139.0% |
| Revenue (ttm) | 32.96M +354.4% |
| Net Income | -143.64M |
| EPS | -32.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65 |
| Open | 16.64 |
| Previous Close | 16.65 |
| Day's Range | 16.48 - 16.65 |
| 52-Week Range | 4.35 - 35.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inf... [Read more]
Financial Performance
In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.
Financial numbers in USD Financial StatementsNews
B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff
B. Riley would be an “aggressive buyer” of Cue Biopharma (CUE) following weakness after the full Phase 2 disclosure. The data “came in ahead of our base case on every…
Cue Biopharma Transcript: Study result
Phase II results for CUE-221 in CSU showed robust, dose-responsive efficacy, with high-dose CUE-221 achieving sustained complete resolution of hives and a statistically significant advantage over omalizumab at 12 weeks off drug. The dual mechanism of action supports potential for disease modification. Plans for phase II-B/III in CSU and phase II in food allergy are underway.
Cue Biopharma Press release: Study result
Cue Biopharma issued a press release on September 21, 2026, disclosing material business information to investors.
Cue Biopharma Slides: Study result
Cue Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on September 21, 2026.
Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint
Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a related company of Ascendant Health Limited. The…
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for different...
Cue Biopharma initiated with a Buy at B. Riley
B. Riley initiated coverage of Cue Biopharma (CUE) with a Buy rating and $83 price target The firm says the company’s near-term opportunity is in allergy. CUE-221 is an anti-IgE…
Cue Biopharma registers to sell 1.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.5M shares of common stock. The company is not selling any…
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported ...
Cue Biopharma Quarterly report: Q2 2026
Cue Biopharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
Cue Biopharma Earnings release: Q2 2026
Cue Biopharma released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Cue Biopharma Registration statement: Registration filing
Cue Biopharma filed a registration statement on August 12, 2026, providing details about a securities offering with the SEC.
Cue Biopharma appoints James Ahlers as CFO
Cue Biopharma (CUE) announced the appointment of James Ahlers as CFO. Ahlers will report to president and CEO Shao-Lee Lin. Prior to joining Cue, Ahlers served for nearly two decades…
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced...
Cue Biopharma Slides: Corporate presentation
Cue Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on July 17, 2026.
Cue Biopharma appoints Dominic Borie as chief medical officer
Cue Biopharma (CUE) announced the appointment of Dominic Borie as chief medical officer, and head of research and development. He reports to president and CEO Shao-Lee Lin. Most recently, he…
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company...
Cue Biopharma to sell 1.418M shares at $33.21 in private placement
Cue Biopharma (CUE) announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 1.418M shares of common stock at…
Cue Biopharma Announces $50.0 Million Private Placement
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for im...
Cue Biopharma files to sell 551,724 shares of common stock for holders
16:07 EDT Cue Biopharma (CUE) files to sell 551,724 shares of common stock for holders
Cue Biopharma Registration statement: Registration filing
Cue Biopharma filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
Cue Biopharma registers to sell 4.09M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 4.09M shares of common stock. The company is not selling any…
Cue Biopharma Transcript: Jefferies Global Healthcare Conference 2026
Precision immunoengineering drives a portfolio targeting allergic and autoimmune diseases, with CUE-221 and CUE-401 advancing through key clinical milestones. CUE-221 shows rapid, durable IgE suppression and is benchmarked against omalizumab, while CUE-401 targets regulatory T cell expansion for autoimmune therapy.
Cue Biopharma Slides: FY 2026
Cue Biopharma has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Cue Biopharma Registration statement: Registration filing
Cue Biopharma filed a registration statement on June 3, 2026, providing details about a securities offering with the SEC.